Halifax-based Sona Nanotech will begin clinical trials in Toronto this week in which 500 emergency room patients suspected of having COVID-19 will use the company’s saliva-based rapid test.
The trials come as the company, whose shares are listed on the Canadian Securities Exchange, has arranged with Canaccord Genuity Corp. a facility that may allow it to raise as much as $10 million by selling shares.
Specializing in medical applications of nanotechnology, Sona Nanotech last year began to apply its technology to a rapid test for COVID-19, which would help meet the need for fast, affordable